Prominent role of relaxin in improving postinfarction heart remodeling: Clues from in vivo and in vitro studies with genetically engineered relaxin-producing myoblasts

Annals of the New York Academy of Sciences

Volumn 1160, Issue , 2009, Pages 269-277

  Bani, Daniele ^a   Nistri, Silvia ^a   Formigli, Lucia ^a   Meacci, Elisabetta ^a   Francini, Fabio ^a   Zecchi Orlandini, Sandra ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

C2C12 myoblasts; Heart remodeling; Myocardial infarction; Relaxin; Stem cells

Indexed keywords

RELAXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; EXTRACELLULAR MATRIX; GENE THERAPY; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; STEM CELL TRANSPLANTATION; SWINE;

SUIDAE;

EID: 64549149755     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03781.x     Document Type: Conference Paper

References (45)

1. Jaber, W.A. & D.R. Holmes Jr. 2007. Outcome and quality of care of patients who have acute myocardial infarction. Med. Clin. North Am. 91: 751-768.
2. Rubart, R. & L.J. Field. 2006. Cardiac regeneration: repopulating the heart. Annu. Rev. Physiol. 68: 29-49.
3. Rubart, R. & L.J. Field. 2008. Stem cell differentiation: Cardiac repair. Cell Tissues Organs 188: 202-211.
4. Vacanti, C.A. 2006. The history of tissue engineering. J. Cell. Mol. Med. 10: 569-576.
5. Anversa, P. & J. Kajstura. 1998. Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ. Res. 83: 1-14.
6. Messina, E., L. De Angelis, G. Frati, et al. 2004. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95: 911-921.
7. Müller, P., A.P. Beltrami, D. Cesselli, et al. 2005. Myocardial regeneration by endogenous adult progenitor cells. J. Mol. Cell. Cardiol. 39: 377-387.
8. Bearzi, C., M. Rota, T. Hosoda, et al. 2007. Human cardiac stem cells. Proc. Natl. Acad. Sci. USA 104: 14068-14073.
9. Torella, D., G.M. Ellison, S. Méndez-Ferrer, et al. 2006. Resident human cardiac stem cells: Role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat. Clin. Pract. Cardiovasc. Med. 3 (Suppl. 1): S8-S13.
10. Caplice, N.M. 2006. The future of cell therapy for acute myocardial infarction. Nat. Clin. Pract. Cardiovasc. Med. 3 (Suppl. 1): S129-S132.
11. Marín-García, J. & M.J. Goldenthal. 2006. Application of stem cells in cardiology: where we are and where we are going. Curr. Stem Cell Res. Ther. 1: 1-11.
12. Meyer, G.P., K.C. Wollert & H. Drexler. 2007. The role of stem cells in the post-MI patient. Curr. Heart Fail. Rep. 4: 198-203.
13. Ramos, G.A. & J.M. Hare. 2007. Cardiac cell-based therapy: Cell types and mechanisms of actions. Cell Transplant. 16:951-961.
14. Dimmeler, S., J. Burchfield & A.M. Zeiher. 2008. Cell-based therapy of myocardial infarction. Arte-rioscler. Thromb. Vasc. Biol. 28: 208-216.
15. Reinecke, H., V Poppa & C.E. Murry. 2002. Skeletal muscle stem cells do not transdifferentiate into car-diomyocytes after cardiac grafting. J. Mol. Cell. Cardiol. 34: 241-249.
16. Leobon, B., I. Garcin, P. Menaschè, et al. 2003. My-oblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc. Natl. Acad. Sci. USA 100: 7808-7811.
17. Berry, M.F., A.J. Engler, Y.J. Woo, et al. 2006. Mes-enchymal stem cell injection after myocardial infarction improves myocardial compliance. Am. J. Physiol. Heart Circ. Physiol. 290: H2196-H2203.
18. Gnecchi, M., H. He, N. Noiseux, et al. 2006. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 20: 661-669.
19. Du, X.J. 2007. Re-modelling 'hostile' milieu of diseased myocardium via paracrine function of transplanted cells or relaxin. J. Cell. Mol. Med. 11: 1101-1104.
20. Ye, L., H.K. Haider & E.K.W. Sim. 2006. Adult stem cells for cardiac repair: A choice between skeletal myoblasts and bone marrow stem cells. Exp. Biol. Med. 231: 8-19.
21. Haider, H.K., L. Ye, S.J. Jiang, et al. 2004. Angiomyo-genesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J. Mol. Med. 82: 539-549.
22. Ye, L., H.K. Haider, R. Tan, et al. 2007. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 116 (11 Suppl.): I1 13-I120.
23. Dschietzig, T. & K. Stangl. 2002. Relaxin: A pregnancy hormone as a central player of body fluid and circulation homeostasis. Cell. Mol. Life Sci. 59: 1-13.
24. Bani, D. & M. Bigazzi. 2005. Clinical aspects and therapeutic perspectives of relaxin. Curr. Med. Chem. Immunol. Endocr. Metab. Agents 5: 403-410.
25. Samuel, C.S., X.J. Du, R.A.D. Bathgate, et al. 2006. Relaxin' the stiffened heart and arteries: The therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol. Ther. 112: 529-552.
26. Nistri, S., M. Bigazzi & D. Bani. 2007. Relaxin as a cardiovascular hormone. Physiology, pathophysi-ology and therapeutic promises. Cardiovasc. Hematol. Agents Med. Chem. 5: 101-108.
27. Formigli, L., A.M. Perna, E. Meacci, et al. 2007. Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodeling. J. Cell. Mol. Med. 11: 1087-1110.
28. Bani Sacchi, T., M. Bigazzi, D. Bani, et al. 1995. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br. J. Pharmacol. 116: 1589-1594.
29. Unemori, E.N., M. Lewis, J. Constant, et al. 2000. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen. 8: 361-370.
30. Samuel, C.S., E.N. Unemori, I. Mookerjee, et al. 2004. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fib rosis in vivo. Endocrinology 145: 4125-4133.
31. Silvertown, J.D., J. Ng, T. Sato, et al. 2006. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int. J. Cancer 118: 62-73.
32. Beltrami, A.P., L. Barlucchi, D. Torella, et al. 2003. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763-776.
33. Wu, S.M., K.R. Chien & C. Mummery. 2008. Origins and fates of cardiovascular progenitor cells. Cell 132: 537-43.
34. Taylor, M.J. & C.L. Clark. 1994. Evidence for a novel source of relaxin: Atrial cardiocytes. J. Endocrinol. 143: R5-R8.
35. Dschietzig, T., C. Richter, C. Bartsch, et al. 2001. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 15: 2187-2195.
36. Osheroff, P.L. & W. Ho. 1993. Expression of relaxin mRNA and relaxin receptor in postnatal and adult rat brain and hearts. J. Biol. Chem. 268: 15193-15199.
37. Hsu, S.Y., K. Nakabayashi, S. Nishi, et al. 2002. Activation of orphan receptors by the hormone relaxin. Science 295: 671-674.
38. Fisher, C., C. Berry, L. Blue, et al. 2003. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89: 879-881.
39. Kupari, M., T.S. Mikkola, H. Turto, et al. 2005. Is the pregnancy hormone relaxin an important player in human heart failure? Eur. J. Heart Fail. 7: 195-198.
40. Dschietzig, T., C. Bartsch, C. Richter, et al. 2003. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: Attenuation of endothelin-1-mediated vasoconstriction by stimulation of en-dothelin type-B receptor expression via ERK-1/2 and nuclear factor-κB. Circ. Res. 92: 32-40.
41. Conrad, K.P. & J. Novak. 2004. Emering role of relaxin in renal and cardiovascular function. Am. J. Physiol. Integr. Comp. Physiol. 287: R250-R261.
42. Perna, A.M., E. Masini, S. Nistri, et al. 2005. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 19: 1525-1527.
43. Dschietzig, T., E. Unemori, S. Wood, et al. 2007. A pilot safety and dose-finding trial of intravenous recombinant relaxin in compensated congestive heart failure (abstr. 2438). Eur. Heart J. 28 (Suppl.): 387.
44. Koyanagi, M., R.P. Brandes J. Haendeler, et al. 2005. Cell-to-cell connection of endothelial progenitor cells with cardiac myocytes by nanotubes: A novel mech-anismfor cell fate changes? Circ. Res. 96: 1039-1041.
45. Muller-Borer, B.J., W.E. Cascio, G.L. Esch, et al. 2007. Mechanisms controlling the acquisition of a cardiac phenotype by liver stem cells. Proc. Natl. Acad. Sci. USA 104: 3877-3882.